Hormonal
Islet amyloid polypeptide (IAPP) aggregation into small soluble oligomers causes beta-cell death via membrane disruption and oxidative stress, contributing to the loss of beta-cell mass in type 2 diabetes.
This research highlights that beta-cell failure in type 2 diabetes is actively driven by toxic protein aggregates (IAPP), not just passive aging. This suggests that therapies targeting amyloid formation (like pramlintide analogs or small molecule inhibitors) could preserve remaining beta-cell function, offering a pathway to slow disease progression beyond just lowering blood sugar.
Recent in vitro studies suggest that the cytotoxic species responsible for islet amyloid-induced (cid:1)-cell death are formed during the very early stages of islet amyloid formation, when islet amyloid polypeptide aggregation commences.
Why this rating
Strong evidence from transgenic animal models and in vitro studies, though human causal proof is inferred from correlation and model systems.
Source
Islet Amyloid: A Critical Entity in the Pathogenesis of Type 2 Diabetes
Rebecca L. Hull et al. · The Journal of Clinical Endocrinology & Metabolism · 2004
DOI 10.1210/jc.2004-0405
More from this paper
- Insulin resistance and obesity increase the secretory demand on beta-cells, which accelerates the formation of cytotoxic IAPP aggregates and amyloid deposition.Good
- Small, soluble IAPP oligomers (prefibrillar assemblies) are the primary cytotoxic species responsible for beta-cell death, whereas mature amyloid fibrils are less cytotoxic.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →